the new and unexpected solution against baldness

Androgenic alopecia, better known as male or female pattern baldness, is one of the most common causes of hair loss all over the world. The most common treatment is the use of topical minoxidilbut it is not a great miracle either because its effectiveness is limited by many factors. Now a group of researchers they have found a solution quite unexpected in the sweeteners that we use on a daily basis to make the treatment more effective. The problem. As we say, topical minoxidil can be affected by the simple fact of have a low solubility in water, making it very difficult for it to pass through the skin. This means that alcohol has to be used as an excipient in the treatment, which generates other side effects such as itching. That is why the study published in the prestigious magazine Advanced Healthcare Materials reveals that the stevioside (STV), a natural compound extracted from the plant stevianot only dramatically improves the absorption of minoxidil, but can be used to create a much more effective delivery system. A sweetener. The scientists’ idea was to use stevioside for its dual function. On the one hand, as a powerful agent to dissolve minoxidil (MXD) and, on the other, as the main material to manufacture an innovative microneedle patch that can later be used in the presentation of the medicine. As. Stevioside is an amphipathic molecule, which means that it has a part that attracts water and another that repels it. This property is very important to be able to create small spheres that are called micelles in an aqueous solution, creating a core where poorly soluble drugs such as minoxidil can comfortably lodge. To understand it, it acts as the ‘vehicle’ that minoxidil uses to cross customs, which are our biological membranes. And the results of the research have been quite good. The study found that stevioside increased the solubility of minoxidil by up to 47 mg/ml, which is approximately 18 times higher than that of minoxidil alone. Microneedling. To overcome the skin barrier, the researchers designed a patch with soluble microneedles made from the mixture of stevioside and minoxidil itself. These microneedles, invisible to the naked eye, painlessly penetrate the outermost layer of the skin and dissolve, releasing the drug directly into the area where the hair follicles are located. This is much better than using it topically with a spray where we have that problem of it not penetrating. Applying. In this way, we have a much more precise application method that also avoids the effects of having to use a metal microneedle. In the laboratory, it has been seen that a release of 85% of the drug and a retention in the skin of 18% is achieved in 24 hours. These numbers far exceed the results achieved with a traditional topical application with an alcohol solution where retention is only 2%. And this is the key for the drug to act in the hair follicle for a longer amount of time before it is metabolized. Put to the test. To see the potential of this new application of the treatment, the test was done on animals in the laboratory. To do this, the animals induced alopecia in the mice and received treatment with the microneedle patch compared to the standard minoxidil solution and a control group. As days passed, the group treated with the stevioside and minoxidil patch showed significantly more hair growth. Specifically, after 35 days of treatment, the area treated with the patch had 67.5% new hair coverage. In comparison, the conventional minoxidil solution only achieved 25.7% coverage in the same period. But it doesn’t stop there, since it was also clearly seen that the patch was much more effective in reactivating the hair follicles to quickly move into the growth phase. A new way. Although human studies are still needed to confirm these findings, this research opens a completely new avenue to combat alopecia. A natural, safe sweetener already approved for consumption could be the key to developing a new generation of hair treatments that are more effective, comfortable and with fewer side effects. Images | Gustavo Sanchez In Xataka | The great promise of science to end baldness is not a transplant or a medicine: it is a vaccine

Minoxidil looked like the great miracle medication against baldness. A pharmaceutical company financed by Google has just overcome it

The fight against alopecia is A thriving market. The first laboratory to achieve the “miracle treatment” that manages to avoid or reverse androgenic alopecia (conventional hair loss associated with age) could take a lucrative prize comparable with the success of formulas such as Ozempic. One of the best positioned laboratories in this race seems to be Pelage Pharmaceuticals. Preliminary results. A few days ago, the Pelage Pharmaceuticals laboratory announced “positive” preliminary results in the second phase of its clinical trials of the compound PP405. According to its announcement, the formula showed a quick and statistically significant response in these trials. PP405. The compound developed by this company, pp405, is designed for topical application and with the aim of reactivating latent follicular stem cells (HFSC), thus allowing the restoration of hair growth. According to Explain the laboratorythese cells usually alternate latency and activity cycles when they work conventionally. However, with age or in response to certain external or internal stimuli, these cells can be “blocked” in the sleeping phase of this oscillation. As highlighted, this state of latency does not imply its disappearance or loss of viability. Test treatment seeks to “restore the regenerative capacity” of these follicles, which entails the recovery of capillary growth. 78 participants. Preliminary results published by the company They belong to phase 2a of clinical trials of the compound. It is a randomized and controlled study in which 78 participants, men and women with androgenic alopecia have taken part. The participants were divided between the experimental group and control group or placebo: the participants of the experimental group applied the compound in their scalp for four weeks; while the control group received a placebo. After four weeks of application, a 12 weeks were monitored to check the effects on the participants. Results. The results now presented do not correspond to those obtained after the essay but to their eighth week (after four weeks of treatment and four subsequent monitoring). The responsible team observed that among men with more advanced baldness, 31% Of these they showed a 20% increase in capillary density. They stood out for this reason the speed of the response to treatment, at least in principle faster than that observed in contemporary treatments. A crucial difference. However, the key to this treatment was in its effect on inactive follicles. The experiment showed regenerative potential both in the areas of weak growth and in the areas where the hair was no longer growing. The treatments we have in the present are useful when reinforcing growth in weakened but active follicles, not those that have already fallen in a state of latency. “These early clinical results reinforce the potential of our approach to go beyond the slowdown of the hair loss process and directly attack the hair follicle tegeneration,” pointed in a press release Christina Weng, medical director of Pelage Pharmaceuticals. A long way to go. The results are preliminary and correspond to a study conducted in a limited sample, so we will have to wait for the company to give new data on the drug evaluation process. According to the laboratorythe last stage of this process, phase 3 of clinical trials, could begin in 2026. The support of a giant. The origin of the project is in the work carried out in the last decade by researchers at the University of California Los Angeles and other institutions. According to the company, the development achieved the support of investors led by Google Ventures. In Xataka | The hair industry in Türkiye has a new enemy: a protein that protects us from baldness Image | Donald Teel

A protein that protects us from baldness

In recent years we have seen the rapid expansion of hair surgery as an effective way to fight hair loss, alopecia. However, we are still far from finding effective and efficient solutions, and that do not require passing through the operating room. MCL-1. Now, an international team of researchers has found a protein Linked to hair growth, a “guardian” against hair loss. The discovery opens a new route of research in the field of alopecia and capillary health. It is the MCL-1 protein, a protein belonging to the BCL-2 protein family. This group of protein performs An important role In cell apoptosis, programmed cell death. HFSC. The team detected the importance of these proteins in the functioning of the stem cells of the hair follicle or HFSC (HAIR Follicle Stem Cells). These cells regulate hair growth With its activation and inactivation. A fragile balance. Capillary growth depends on the work of these HFSC cells but also on their ability to start their apoptosis, their self -destruction, at the right time, giving way to new cells that continue their work. However, this is a fragile balance that can be broken when cell stress accelerate this scheduled death. According to the new work, MCL-1 proteins exercise a role of protectors of this balance. The absence of this unaction that includes the activation of the P53 genea sign of stress that ultimately carries cell death. In mice. The process was proven in mice. The team “deactivated” MCL-1 in these mice and then removed the animal’s hair in some areas of its skin. Thus observed the appearance of cell stress and activation of the P53 pathway. The result: the hair did not grow again. The details of the study were published In an article In the magazine Nature Communications. An upward market. Half -World Laboratories compete in the race for developing treatments that avoid hair loss. It is a career that promises a succulent prize: the hair loss industry already moves millions in surgeries and treatments capable of slow down the rhythm to which we lose hair. In addition, Ozempic’s success reminds us of the great economic potential of pharmacoesthetic. Today we have potential formulas, which include From the microarn (small RNA particles) even vaccines of messenger RNA (RNM) as those used in the fight against COVID; Going through the “cloning” of hair, a treatment that, although promising, also demands the passage through the operating room. In Xataka | The industry wants us not to fall hair never again. And it is getting closer to getting it Image | Kaboomps.com

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.